Overview:
Tavaborole is a novel topical antifungal drug based on boron intended to treat onychomycosis, a fungal infection of the nails and nail beds mostly caused by Trichophyton rubrum or Trichophyton mentagrophytes. The United States Food and Drug Administration (USFDA) approved it in 2014.
Drug Group:
Tavaborole topical solution is a member of the antifungal pharmaceutical class and is typically used to treat fungal toenail infections characterized by symptoms like nail discoloration, splitting, and irritation.
Available Doses and Dosage Forms:
Tavaborole is supplied as a transparent, colorless topical solution. It is applied to the affected toenail, and any skin contact should be avoided or washed off immediately. It is available as a five-percent topical solution, and the amount of Tavaborole in one milliliter of solution is 43.5 mg.
For Patients:
How Does Tavaborole Work in Treating Toenail Fungus?
Toenail infection is a common fungal infection that mainly affects toenails. It can also affect fingernails, though it happens less frequently. This disorder develops when fungus enters the space between the nail and the nail bed or the tissue beneath the nail. A crack or opening in the skin (for example, a crack) surrounding the toe is usually the source of this intrusion, giving the fungus a place to enter and cause an infection.
A fungal infection of the nail unit is called onychomycosis. Tinea unguium is the term for onychomycosis caused by dermatophytes (a type of mold that requires a protein called keratin to grow). Onychomycosis is a widespread term that is brought on by yeasts, dermatophytes, and saprophytic molds. Although toenail onychomycosis is more frequent, it can infect both fingernails and toenails.
The Tavaborole topical solution aims to treat fungal or yeast infections of the toenails. This drug works by removing the yeast or fungus causing the infection or completely stopping its growth.
Who Is Affected by Toenail Fungus?
Although toenail fungus can affect anyone, older adults, especially those over 60, are likelier to get it. Athlete's foot (a type of fungal infection that starts between the toes), diabetes (blood glucose is elevated), hyperhidrosis (excessive sweating), and psoriasis (a chronic illness where skin cells proliferate excessively quickly due to an overactive immune system). Skin patches, which are scaly and inflamed, are among the disorders that can raise the chance of getting toenail fungus. Toenail fungus can also be more common in people with a history of nail damage, peripheral vascular disease (circulatory impairment where blood flow to the limbs is decreased due to constricted blood vessels), weaker immune systems from HIV (human immunodeficiency virus), or autoimmune illnesses (overactive immune system resulting in damage to the body’s cells), and poor blood circulation. The mentioned features increase the vulnerability to toenail fungal infections, underscoring the significance of appropriate preventive and management tactics, especially for those with these predisposed conditions.
What Are the Things to Inform the Doctor Before Taking Tavaborole?
Patients with allergies to Tavaborole, other drugs, or any substances in the Tavaborole topical solution should inform their doctor and pharmacist. Discussing all medications, prescription and over-the-counter, and any vitamins, supplements, and herbal products taken or intended to be used is crucial. This information allows the physician to monitor for possible adverse effects or change prescription dosages as needed.
Additionally, patients must report any current or former medical issues. Notifying the doctor is essential if the person is breastfeeding, planning a pregnancy, or is already pregnant. If pregnancy occurs during Tavaborole topical solution usage, contacting the doctor promptly is recommended.
How Is Tavaborole Administered?
For 48 weeks, the topical treatment Tavaborole, which is applied to the toenails, must be administered continuously at the same time every day. It is important to follow the directions on the prescription label and ask the doctor or pharmacist for clarification if necessary. Users must adhere to the recommended dosage and frequency to prevent overuse or underuse.
Tavaborole should only be applied to the infected toenails; the surrounding skin should not come into contact with the medication. It is crucial to keep the mouth, nose, eyes, and vagina clear. Additionally, since Tavaborole topical solution is flammable, users should avoid heat and flames while applying.
How Is Tavaborole Applied?
Make sure the toenails are clean and dry before applying the topical solution. The person must unwrap the dropper and put it into the bottle before applying the Tavaborole topical solution for the first time. After removing the lid, they must discard it. The dropper will be filled with medication by pressing and releasing the bulb. Squeeze the bulb carefully to distribute enough medication to cover the entire toenail, which may require more than one drop. Any contact between the dropper and the toenail should be avoided. They should apply the medication to the entire toenail using the tip of the dropper, then place it under the tip to cover the skin underneath with medication.
Using a tissue, remove any extra medication that may have gotten onto the surrounding skin, keeping the drug inside the toenail. If multiple toenails are affected, the entire process is repeated for them. The dropper tip needs to be firmly replaced in the bottle after use. A few minutes should be given so that the toenails dry out properly. Hands should be washed with soap and water after Tavaborole application.
Dietary Instructions:
People should stick to their regular diet unless directed otherwise by a healthcare provider.
Side Effects:
People who experience any of the following side effects from Tavaborole topical solution should contact their doctor right away if their symptoms worsen or do not go away:
-
The skin surrounding the affected toenail(s) is peeling, red, itchy, or swollen.
-
Developing ingrown toenails (a condition where a toenail's side or corner grows into the skin).
Missed Dose:
When a dose (topical application of the medicine) is forgotten, it should be taken as quickly as possible. If it is time for the next scheduled dose, it is advised to omit the missed dose and resume the regular dosing plan. It is crucial to avoid adding more solutions to make up for a missed dose.
Overdose:
In the event of an overdose, it is critical to act quickly. The poison control center should be immediately contacted. Contact emergency authorities right away if the person has passed out, is having a seizure, is having trouble breathing, or cannot wake up.
Storage:
-
Medicine Storage
-
Keep it out of children's reach, securely closed, and in its original container.
-
Keep it out of the bathroom and store it at room temperature, away from open fires, extreme heat, and dampness.
-
Dispose of the drug after three months of usage or opening the bottle.
-
-
Medicine Disposal
-
Avoid disposing of Tavaborole in the trash or flushing it down the drain.
-
Medication take-back programs are the most effective approach to get rid of it.
-
Ask the local garbage or recycling department or the pharmacist for advice if there is no take-back program.
-
Use child-resistant containers wherever feasible to keep all medications out of the reach of young children.
-
Keep the medicine in a safe location that is out of children's sight and access, and lock safety caps.
-
For Doctors:
Indication: Tavaborole treats onychomycosis, a condition affecting the toenails caused by the fungus Trichophyton mentagrophytes or Trichophyton rubrum.
Contraindication - None.
What Are the Pharmacological Aspects of Tavaborole?
-
Description -
-
Empirical Formula: 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole.
-
Molecular Weight: C7H6BFO2.
-
Appearance: Powdered Tavaborole is white to off-white.
-
Solubility: It dissolves readily in ethanol and propylene glycol but is only marginally soluble in water.
-
Inactive Ingredients: Propylene glycol, edetate calcium disodium, and alcohol are examples of inactive substances.
-
-
Mechanism of Action: Tavaborole inhibits fungal protein synthesis by impeding cellular protein synthesis via the formation of an adduct with cytoplasmic leucyl-aminoacyl transfer RNA (tRNA) synthetase, which is how it displays its antifungal effect. The suppression of aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS) is the mechanism underlying this inhibition. Tavaborole is effective against various fungal strains of Trichophyton mentagrophytes or Trichophyton rubrum, as demonstrated by its action against different strains in both clinical infections and in vitro experiments.
-
Pharmacodynamics: Tavaborole is not expected to appreciably extend QTc to a clinically significant level at therapeutic levels.
-
Pharmacokinetics: Tavaborole is heavily metabolized by the body, with the kidneys being the primary disposal organ. Tavaborole and its metabolites are mostly eliminated in the urine. When Tavaborole was given topically, it reached a steady state after 14 days of daily administration, with peak concentrations being reached after single and repeated doses. Furthermore, comparable pharmacokinetic profiles were seen in trials conducted on teenagers between 12 and 17. In lab experiments, Tavaborole had no effect on or interference with the activity of cytochrome P450 enzymes, which are important in drug metabolism.
-
Nonclinical Toxicology: Tavaborole administered orally or topically for 104 weeks in rats and mice did not result in cancer at dosages up to 14 times (oral) and 89 times (topical) the recommended human dose. In numerous experiments, it also failed to exhibit any indications of harming genes. Furthermore, in rats given doses up to 107 times the recommended quantity, it did not affect the ability to conceive.
Clinical Studies:
Two sizable phase III trials for toenail fungus assessed the safety and efficacy of the Tavaborole topical solution, a novel antifungal therapy, at five percent. Two groups of adults with this condition were formed, and during 48 weeks, one group received Tavaborole while the other group received a non-medicated solution (a vehicle). By week 52, the primary objective was to determine if Tavaborole could eradicate the infected toenail. Enhancing the look and safety of nails were among the other objectives.
The results indicated that, compared to the non-medicated treatment, Tavaborole was substantially better at getting rid of the fungus and improving the appearance of the nails. When using Tavaborole, some patients developed moderate skin responses, such as itching, redness, or peeling.
The length of the study was a constraint, though. Given that its advantages exceed its disadvantages, Tavaborole seems reasonable for treating toenail fungus.
Specific Considerations:
-
Pregnancy - In animal trials, Tavaborole administration during pregnancy caused embryo-fetal toxicity and abnormalities, usually at dosages much higher than the upper limit of what is advised for humans. Adverse effects on fetal development were observed in rats and rabbits after oral doses and in rabbits after topical application. These effects included lower fetal body weight, skeletal abnormalities, and increased embryo-fetal resorption. However, no developmental damage was seen at concentrations closer to human exposure levels. Despite these results, the possible risk to expectant mothers is still unknown because there is no data on pregnancies in humans. When prescribing Tavaborole to pregnant patients, doctors should balance the possible hazards against the advantages.
-
Nursing Mother - There is not much information on Tavaborole’s presence in human milk, how it affects breastfed babies, or how it affects nursing mothers' ability to produce milk when applied topically. It is noteworthy that Tavaborole can be absorbed throughout the body. Since clinical data during lactation is lacking, it is difficult to determine the risk that Tavaborole poses to a breastfed newborn. Hence, medical professionals should carefully consider the advantages of breastfeeding for the mother's health and development versus her clinical need for Tavaborole and any possible risks to the infant from Tavaborole or the underlying ailment.
-
Pediatric Patients - Patients six years and older have shown Tavaborole to be safe and effective. Substantial evidence from appropriately planned and controlled research, including adult patients, validates this conclusion. The use of Tavaborole in pediatric populations is further supported by findings from an open-label pharmacokinetics study of Tavaborole in people 12 to younger than 17 years.
-
Geriatric Patients - A significant proportion of participants in clinical trials assessing Tavaborole were 65 or older, with a smaller subgroup of individuals 75 and older. There were no appreciable differences in safety or effectiveness between these age groups compared to younger participants. However, it is important to acknowledge that older people may be more sensitive to some consequences, yet it is unclear how precisely sensitive they are.
